UCB (UCBJF) Projected to Release Earnings on Thursday

UCB (OTCMKTS:UCBJF) is anticipated to release its resultson Thursday, July 30th. Analysts expect UCB to post earnings of $5.81 per share and revenue of $4.6379 billion for the quarter.

UCB Trading Down 2.6%

Shares of UCBJF stock opened at $280.49 on Wednesday. The business’s fifty day moving average price is $292.53 and its 200 day moving average price is $300.64. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a 1-year low of $207.00 and a 1-year high of $345.39.

Analyst Ratings Changes

Separately, Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.